Navigation Links
New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma

mately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. will co-promote VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
5. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
8. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
9. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
10. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
11. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies
Post Your Comments:
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com announces that ... its catalogue: Global Coatings for Medical ... This report analyzes the worldwide ... Million by the following Product Segments: Active Coatings, ... report provides separate comprehensive analytics for the US, ...
(Date:8/20/2014)... 20, 2014 ApolloDx™ today announced it will ... a special event at the company,s office in ... 5, 2014. The event, which will start at 10:00 ... www.apollodx.com .    "We believe our ... Jared Bauer , Co-Founder and Managing Partner of ApolloDx. ...
(Date:8/20/2014)... Aug. 20, 2014   Easy Breathe , the fastest growing ... " Easy Blog " - has received more than 4.5 million ... "We are thrilled that so many people are finding our ... of Easy Breathe. "We,re committed to making sleep apnea more widely ... stay informed about sleep apnea news , troubleshooting advice ...
Breaking Medicine Technology:Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 3Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 4
(Date:8/20/2014)... 20, 2014 Get the report here: ... mergermarket presents “Deal Drivers 2014 Half Year Report for ... M&A activity in both North and South America, with ... About Merrill DataSite     , Merrill DataSite is a ... the due diligence process by providing a highly efficient ...
(Date:8/20/2014)... Angeles, CA (PRWEB) August 20, 2014 ... it is bringing on Wrench Advisors as a ... tasks including international large accounts. , As Wrench ... sales consultants can help your organization plan and ... executives and global distribution channels. Our experience developing ...
(Date:8/20/2014)... In its latest blog post, A Forever Recovery ... clients off to a great start and gives them a ... an important and possibly life-changing – perhaps even life-saving – ... understand the insidious nature of drug abuse: it doesn’t discriminate. ... targets a certain socioeconomic group, such as inner-city youth or ...
(Date:8/20/2014)... The award-winning plastic surgery group, The Aesthetic ... throughout Houston to a third office, located in Katy, ... building. ACPS plastic surgeon Dr. Rolando Morales said the ... has risen to become one of the largest, most ... since its establishment in 1996 by plastic surgeons Dr. ...
(Date:8/20/2014)... Antonio, TX (PRWEB) August 20, 2014 Texas ... their new study. The study will help test the effectiveness ... who suffer from high cholesterol may be eligible to participate ... too much cholesterol in the blood can lead to cardiovascular ... States. Lowering cholesterol can help reduce the risk of heart ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Deal Drivers 2014 Half Year Report for the Americas 2Health News:Biocide Systems Announces Partnership with Wrench Advisors 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3Health News:Aesthetic Center for Plastic Surgery Expands Its Reach in Texas 2Health News:Texas Medical Research Associates Announce New Study 2
... DNA vaccine trials conducted against the AIDS/HIV virus. The ... completed among 40 HIV- negative // volunteers. ... of vaccine biology. It involves direct injection of one ... human body. These vaccines precipitate an immune response so ...
... new generation stents that are deigned for slow release of ... stents according to a recent study conducted on stents used ... effectively prevent the overgrowth of scar tissue, thereby reducing incidence ... can either be inserted into a grafted vein or into ...
Fatehpur Sikri, Mughal Emperor Akbar's dream city, has come up some new finds, thanks to the labourious// excavatory work of the Archaeological Survey of India (ASI). ,According to Munazar Ali, a mo...
... from the University of Lund in Sweden have conducted ... of type 2 diabetes // . ,Exposure ... asthma, diabetes and many cancers. ,High levels of ... dichloro-diphenyl-trichloro-ethane or DDT in the blood of diabetic patients ...
... With the ever-increasing unsafe sex practices, massive migration and ... the incidence of the killer disease // amongst the ... ,Several districts of Orissa including Ganjam, Kendrapara, Balasore Nuapada, ... of HIV incidence, which poses a challenge to the ...
... warning German researchers say that loud noise can increase the ... risk is squarely attributed// to the noise related to the ... ,It was found that this noise had a ... the Institute for Social Medicine, Epidemiology and Health Economics at ...
Cached Medicine News:Health News:DNA Vaccine Trials Against HIV Virus In Sweden Nurture Hope 2Health News:Drug-Eluting Stents Ensure Patency Of The Saphenous Vein Grafts 2Health News:High Decibel Levels Raise Heart Disease Risk 2